David Shaw’s Krystal Biotech KRYS Stock Holding History

David Shaw’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$297K	Buy	+800	New	+$239K	﹤0.01%	4419

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

David Shaw's KRYS Position: Q2 2026 in Review

David Shaw sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 996 shares — an estimated $298K sold.

David Shaw first reported a position in KRYS in Q2 2021 and held it in 19 quarters. The position peaked at $14.6M in Q1 2024. 420 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

David Shaw reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
David Shaw sold 996 Krystal Biotech shares in Q2 2026, an estimated $298K.
David Shaw first reported a position in Krystal Biotech in Q2 2021 and held it in 19 quarters.
David Shaw's Krystal Biotech position peaked at $14.6M in Q1 2024.
420 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.